Delving into the Latest Updates on Bruschettini Srl with Synapse

概览

关联

3

项与 Bruschettini Srl 相关的临床试验

NCT05753852

/ Recruiting临床3期

Open Label Extension Study to Investigate Long Term Safety, Tolerability and Efficacy of Tauroursodeoxycholic Acid in Patients With ALS Who Completed the TUDCA-ALS Study

This study will provide extended access to patients and assess longer-term outcomes on patients who have completed the TUDCA-ALS study.

开始日期2021-10-25

申办/合作机构

Humanitas Mirasole SpA

[+9]

NCT03800524

/ Active, not recruiting临床3期

Safety and Efficacy of Tauroursodeoxycholic (TUDCA) as add-on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis (ALS)

This is a Phase III, multi-centre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate Safety and Efficacy of Tauroursodeoxycholic (TUDCA) as add-on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis (ALS).

开始日期2019-02-22

申办/合作机构

Humanitas Mirasole SpA

[+9]

EUCTR2011-003239-76-IT

/ Not yet recruitingN/A

Efficacy and tolerability clinical trial of Lantigen B (A bacterial lysate having immunostimulating activity) in the prophylaxis of respiratory infections, with special reference to patients with allergy to perennial inhalants. Double-blind multicenter, randomized study vs. placebo. - LAN-BR-11-001

开始日期2012-05-07

申办/合作机构

Bruschettini Srl

100 项与 Bruschettini Srl 相关的临床结果

登录后查看更多信息

0 项与 Bruschettini Srl 相关的专利（医药）

登录后查看更多信息

1

项与 Bruschettini Srl 相关的新闻（医药）

2022-07-18

·SYNAPSE

PIAM Farmaceutici acquisisce il 100% di Bruschettini

Deloitte Legal ha assistito PIAM Farmaceutici sia per gli aspetti corporate sia per la negoziazione dell’Acquisition Financing.PIAM Farmaceutici S.p.a. ha acquistato il 100% di Bruschettini, in…

100 项与 Bruschettini Srl 相关的药物交易

登录后查看更多信息

100 项与 Bruschettini Srl 相关的转化医学

登录后查看更多信息